This announcement is a separate document:
中國抗體-B：自願公告SM17在中國1b期臨床試驗完成首例患者給藥
SINOMAB BIO-B: VOLUNTARY ANNOUNCEMENTFIRST PATIENT DOSED IN A PHASE 1b CLINICAL TRIALOF SM17 IN CHINA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.